EMA to Hold its Second Public Meeting on COVID-19 Vaccines
The agency is organizing a second public meeting on January 8, 2021 to discuss the assessment, approval, and roll-out of new COVID-19 vaccines.
The European Medicines Agency (EMA) is organizing a second public meeting regarding the assessment, approval, and roll-out of new COVID-19 vaccines. At the meeting, EMA will discuss plans to ensure the safety of COVID-19 vaccines and the roles that the European Commission and the national public health authorities will play in the roll-out of the vaccines, according to a press release dated Dec. 22, 2020.
The meeting will be held online on January 8 and will be attended by EMA executive director Emer Cooke and members of EMA’s human medicines and safety committees, among others. An online form is being made available for those who wish to submit questions to panelists at the meeting. The agency has requested that these questions be submitted by Dec. 31, 2020.
Source: EMA
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
